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ABSTRACT
Background: There is no single test currently available, which can predict respiratory failure in patients with
amyotrophic lateral sclerosis (ALS) with high sensitivity and specificity. This study explores the potential use of
transcutaneous carbon dioxide (PtcCO2) monitoring in early detection of respiratory failure in ALS.
Methods: This is a prospective observational cohort study consisting of 50 consecutive patients with ALS. The
participants underwent 3 monthly assessments for symptoms of respiratory failure, forced vital capacity (FVC) and
PtcCO2 monitoring. Once respiratory failure was clinically suspected by the treating physician, further follow-up was
stopped. The presence of respiratory failure was confirmed with an overnight capnometry.
Results: Symptoms of respiratory failure were the most powerful tool, alerting the physician to the possibility of
respiratory failure. All the patients where respiratory failure was confirmed on overnight capnometry had symptoms of
respiratory failure. 37% of these patients had FVC of > 50% predicted and only 13% had daytime hypercapnia. None
of the patients had daytime hypercapnia without any other marker of respiratory failure. There was statistically
significant difference between the day time PtcCO2 and median overnight PtcCO2 (p=0.0002).
Conclusions: This study has emphasised the importance of symptom history as a screening tool to suspect respiratory
failure in ALS. Once again, the limitations of FVC in predicting respiratory failure is demonstrated in this study. A normal
daytime PtcCO2 may be falsely reassuring and day time hypercapnia is a late finding which implies established
respiratory failure.
KEY WORDS: Amyotrophic lateral sclerosis Neuromuscular respiratory failure Transcutaneous partial pressure of
carbon dioxide

INTRODUCTION:

bulbar weakness2. Standard current practice is to
screen patients for symptoms of respiratory failure and
supplement this with one or more respiratory function
tests. Forced vital capacity (FVC) is the most commonly
used respiratory function test in many ALS clinics for
this purpose. ALS patients with respiratory failure can
benefit from non-invasive ventilation (NIV) which has
been shown to improve survival as well as quality of
life3. Although the precise timing for NIV initiation for

Regularly screening for evidence of respiratory failure is
an important facet in the management of amyotrophic
lateral sclerosis (ALS)1. Currently there is no single test
which can predict respiratory failure with high sensitivity
and specificity. Moreover, no test of respiratory muscle
strength has significant positive predictive power to
predict hypercapnia in the ALS patients with significant
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routinely screened for respiratory impairment. A cohort
of 50 consecutive patients with ALS, who gave
informed consent, was recruited irrespective of the
duration of their disease. The exclusion criteria were
presence of respiratory failure and inability (due to
mental capacity) or unwillingness to give informed
consent.

maximum benefit has not been established in a clinical
trial, once a patient with ALS reaches the stage of
respiratory failure the average survival is only few
months without respiratory support. Therefore, for
important prognostic and therapeutic implications early
detection of respiratory failure is important. Since the
first ever manifestation of impaired ventilation is
nocturnal hypercapnia, a simple and non-invasive test
to monitor partial pressure of carbon dioxide in the
blood on a regular basis would be very useful in clinical
practice4. The transcutaneous carbon dioxide (TOSCA)
monitor allows transcutaneous measurement of the
partial pressure of carbon dioxide (PtcCO2) along with
oxygen saturation (SpO2), with a probe attached to the
ear lobe5. To our knowledge, there are currently no
studies on the potential benefit of transcutaneous
carbon dioxide monitoring to screen for respiratory
failure in patients with ALS. We hypothesized that if
PtcCO2 is recorded at regular intervals during follow up
clinical assessments, it may help in the early diagnosis
of respiratory failure.

Study tools: Transcutaneous carbon dioxide level
(PtcCO2) was recorded using TOSCA 500, operated in
accordance with the manufacturer’s operating manual.
A disposable ear clip was used to attach the sensor
from the TOSCA monitor to the ear lobe. A contact gel
was applied between the sensor and the skin to
facilitate diffusion. The device was operated on a
“QUICKSTART” mode which warms the sensor to a
temperature of 42°C (increasing the arterial blood
supply in the dermal capillary bed below the sensor)
and gives the reading in 10-15 minutes. In order to
have a consistent approach in screening for symptoms
of respiratory failure, a questionnaire consisting of 18
possible symptoms of respiratory insufficiency was
designed. A detailed search of the literature did not
identify any pre-existing questionnaire which could be
used for this purpose. The questionnaire was based on
symptoms reported by patients with respiratory muscle
weakness (in the literature and clinical experience of
the investigators)6-12. It was interviewer administered
and took 5-10 minutes to complete. The symptoms
were divided into three domains i.e., breathing related
symptoms,
sleep
related
symptoms
and
mental/emotional state. This format was partially
influenced by the format of the ALS functional rating
scale and sleep apnoea quality of life index13 14. Each
question was answered as yes or no, with one mark
awarded for each affirmative answer. The questionnaire
was piloted to ensure the questions were easy to
understand, clear and open ended. The questionnaire
in Table 1 is the final questionnaire developed following
some minor amendments in response to the pilot
experience. A volumetric spirometer (vitalograph® –
Alpha) was used to record FVC. A face mask was used
for the patients not able to achieve a tight mouth seal.
The spirometer was calibrated daily and the best of
three attempts was recorded.

MATERIAL AND METHODS
Study design: This is a prospective observational
cohort study consisting of 50 consecutive ALS patients.
Aims of the Study: This study aims to determine
whether PtcCO2 is a sensitive test for screening for
early type II respiratory failure compared to symptom
history or FVC.
Research Hypothesis: Periodic measurement of
PtcCO2 in the clinic, using this non-invasive method
may help in the early detection of type II respiratory
failure in patients with ALS. We hypothesized that
during the follow-up assessments we will identify some
patients with a raised PtcCO2 (and hence respiratory
failure) but otherwise having no symptoms of
respiratory failure and a preserved FVC. This may allow
us to conclude that periodic recording of PtcCO2 in
otherwise asymptomatic patients is potentially a useful
measure for early detection of respiratory failure in both
limb and bulbar onset ALS.
Standard protocol approval, registration and
patient consent: The study protocol was approved by
Bradford research ethics committee, reference
10/H1302/96. Written informed consent was obtained
from all patients (or carers of patients) participating in
the study.

Measurements: On the registration visit, after
obtaining an informed consent patients underwent the
following assessments:

Study setting and population: The study was carried
out at the Sheffield care and research centre for motor
neurone disorders. In this clinic patients with ALS are
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3. FVC
Only those patients with a normal PtcCO2 (4.6 - 6 kPa)
were recruited. At each 3 monthly subsequent visits
patients underwent the following assessments:

recruited during the recruitment time available.
en trials of this test performed namely MIND
ALERTNESS in which the participants were directed to
play a video game in which he/she had to recognize the
direction of the arrows in a given time.

1. Detailed questioning about the symptoms of
respiratory failure (using a standard questionnaire)
2. TOSCA PtcCO2
3. FVC

Table 2: Baseline characteristics of the study
participants

Once clinically suspected by the treating physician,
respiratory failure was confirmed by overnight
capnometry (using TOSCA500), at which point the
study-specific respiratory assessments were stopped.
Table 1 Screening questionnaire to identify
potential patients with respiratory failure

Evidence of respiratory failure
Table 3 summarises the respiratory parameters at the
time when respiratory failure was suspected by the
clinician and confirmed with an overnight capnometry.
These data suggest that the presence of symptoms of
respiratory failure is the most powerful tool to predict
respiratory failure. FVC and daytime PtcCO2 were
insensitive as FVC of > 70% of predicted and daytime
PtcCO2 of < 5.0 kPa was observed in patients where
respiratory failure was suspected clinically due to
presence of symptoms and those who fulfilled the
criteria of respiratory failure on nocturnal capnometry
(median PtcCO2 ≥ 6 kPa).

RESULTS

Table 3: Respiratory parameters when respiratory
failure suspected and confirmed by overnight
capnometry

The characteristics of study participants are
summarised in Table 2. The average age was 60 years,
58% were male and participants were predominantly
sporadic ALS with limb onset disease. The mean
duration between disease onset and study entry was
39 months. 30 patients reached the primary end point.
8 patients died during follow-up without been
diagnosed with respiratory failure and 6 patients were
lost to follow-up during the course of the study. 6
patients have not reached the primary end point at the
time of writing and are likely to be slow progressing
atypical forms of ALS. Although we hypothesised that
recording transcutaneous PCO2 would be particularly
valuable for patients with poor bulbar function, only 6
patients with severe bulbar dysfunction could be
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used for the analysis of agreement between the two
methods. Pearson correlation coefficient was 0.656.
DISCUSSION
A crucial aspect in the management of patients with
ALS early identification of respiratory compromise.
Respiratory muscle weakness is often unmasked during
sleep, particularly during rapid eye movement (REM)
sleep when the intercostal and accessory muscles of
breathing are inactive and the diaphragm carries the
work of breathing9. A weak diaphragm may fail to allow
adequate ventilation and frequent arousals are required
as a compensatory mechanism to maintain adequate
ventilation, thus reducing total sleep time, REM sleep
and the overall quality of sleep. Hence disturbed sleep,
due to episodes of hypoventilation, is one of the earliest
manifestations of respiratory insufficiency and usually
occurs well before daytime hypoventilation and the
resulting daytime hypercapnia develops9. The
symptoms of “sleep fragmentation” include nocturia,
nightmares, unrefreshing sleep and daytime
somnolence. Symptoms of CO2 retention include
morning headaches, poor appetite, fatigue, cognitive
dysfunction and, as a result, poor quality of life. With
disease progression, patients may develop exertional
dyspnoea, orthopnoea, dyspnoea at rest and anxiety
associated with the feeling of breathlessness1.

* Values only available for 12 patients
Symptoms of respiratory failure
The most common symptoms (present in at least 1/3rd
of the patients at the time of suspected respiratory
failure) are reported in table 4. These questions may
assist in identifying those at risk and in the decision to
investigate a patient further. Cronbach’s alpha (α) was
calculated as a measure of internal consistency of the
responses when respiratory failure was clinically
suspected. The Cronbach’s α for the analysed cohort of
30 patients was 0.7. A Cronbach’s α value between 0.7
and 0.8 is considered as having a strong and positive
correlation of the items of a scale.
Table 4: Most common sympztoms at the
ztime of suspected respiratory failure

In order to objectively assess respiratory function, a
variety of invasive and non-invasive, voluntary and
involuntary respiratory function tests have been
assessed to identify patients with respiratory
impairment and plan timely intervention. However, no
single respiratory test can reliably confirm or exclude
the presence of nocturnal hypoventilation. An FVC of
50% predicts day time hypercapnia with a sensitivity of
53% and specificity of 89%2, demonstrating the
limitations of this test for predicting even late
respiratory failure. Moreover, it is a volitional test which
is often difficult for the patients with severe bulbar
dysfunction to perform. The most appropriate method
to screen for respiratory failure in such patients remains
unclear. The ideal test would be non-invasive, easy to
perform in an out-patient setting and would diagnose
early respiratory failure with high sensitivity. This study
was planned with the aim to evaluate the value of
regular transcutaneous carbon dioxide measurements
in the early detection of respiratory failure. It is
non-invasive and independent of the subject being
tested and findings are easy to interpret (PCO2 > 6.0
kPa = respiratory failure). Although daytime
hypercapnia is reported in the literature as a relatively

Relationship between symptoms and daytime
carbon dioxide level
Figure 1 illustrates the relationship between the
symptoms of respiratory failure and daytime PtcCO2.
The study was not powered for such analysis and hence
within the limits of small number of patients no
relationship between the symptoms of respiratory
failure and daytime PtcCO2 is demonstrated at any of
the follow-up time points.
Relationship between daytime and nocturnal
carbon dioxide levels
Nocturnal transcutaneous capnometry was carried out
when respiratory failure was clinically suspected. The
difference between daytime PtcCO2 and median
overnight PtcCO2 was statistically significant
(p=0.0002). Figure 2 illustrates the Bland-Altman plot

PAKISTAN JOURNAL OF NEUROLOGICAL SCIENCES

25

VOL. 14 (1)

J A N U A R Y- M A R C H 2 0 1 9

predicted was not associated with any symptoms of
respiratory failure. In conclusion, regular PtcCO2
measurements may not help in early identification of
respiratory failure and daytime normocapnia may be
falsely reassuring. Special attention should be given to
the presence of symptoms of respiratory failure and
overnight capnography carried out where clinical
suspicion of respiratory failure is high. Demonstration of
nocturnal hypoventilation (rising PCO2 and falling
SpO2) imply ventilatory failure and the patient may
benefit from intervention with NIV.

late event15 16, the benefit of regular transcutaneous
PCO2 measurements has not been systematically
assessed previously. There are a number of important
lessons learnt in this study. The primary outcome was
detection of daytime hypercapnia when it would not
have been clinically suspected using other parameters.
In the current cohort, no patient was identified to be in
respiratory failure on the basis of daytime PtcCO2 alone.
Most patients (87%) with other features of respiratory
failure and nocturnal hypercapnia, had a normal
daytime PtcCO2. This finding suggests daytime
compensation of ventilation with the voluntary
activation of accessory muscles of breathing and
enhanced activation of the respiratory center as a result
of improved blood biochemistry. The accessory muscle
of respiration and central respiratory drive are both
suppressed during normal sleep9. Hence, daytime
normocapnia may not be considered as indicating the
absence of respiratory dysfunction. The importance of
symptom history is highlighted in this study. In all the
patients who reached the primary endpoint,
development of symptoms of respiratory compromise
alerted the physicians to the presence of respiratory
insufficiency. The most common symptoms identified
are listed in Table 4. Based on the most common
symptoms, the questionnaire used in this study could
be modified further to include only the symptoms listed
in Table 4. The resultant questionnaire, with a certain
cut-off score, is likely to have a strong positive
predictive value in diagnosing respiratory failure.
However, such questionnaire would require further
validation in diagnosing respiratory failure using a bigger
sample size17. A difficulty in this regard is in deciding
which comparator to use as benchmark of respiratory
failure. The best definition of early respiratory failure in
patients with neuromuscular disease is nocturnal
hypercapnia which requires at least nocturnal
transcutaneous capnography, which is time consuming
and expensive. Hence, bedside respiratory function
tests need to be combined with clinical assessment to
select appropriate patients who are most likely to have
nocturnal hypercapnia and may benefit from
intervention with NIV. Once again, the limitations of FVC
in predicting respiratory failure is demonstrated in this
study. Three patients with confirmed nocturnal
hypercapnia had an FVC of greater than 70% predicted.
One patient with an FVC of 95% predicted had 6
symptoms of respiratory failure with a median nocturnal
PtcCO2 of 6.27 kPa. Similarly an FVC as low as 38%
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symptoms and PtcCO2
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Figure 2: Bland-Altman plot of the difference
between the nocturnal and day time PCO2 against
the average of the two measurements
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